Can People with Non-Hodgkin Lymphoma Safely Consume Pine Pollen?

Patients diagnosed with non-Hodgkin lymphoma (NHL) often seek complementary approaches to support their overall health during treatment. One commonly asked question is whether pine pollen—a traditional dietary supplement in some cultures—can be safely consumed. From a clinical oncology perspective, there is no scientific evidence supporting the use of pine pollen as a therapeutic agent for NHL. While pine pollen contains various nutrients, including amino acids, vitamins, and trace minerals, its biological activity in humans has not been rigorously evaluated in controlled trials, particularly in immunocompromised individuals undergoing chemotherapy, immunotherapy, or radiation.

More importantly, safety concerns exist. Pine pollen may possess immunomodulatory properties, and although these effects are poorly characterized, unintended stimulation—or suppression—of immune function could theoretically interfere with standard NHL therapies, such as rituximab-based regimens or CAR-T cell treatments. Additionally, unregulated herbal supplements like pine pollen carry risks of contamination, inconsistent dosing, and potential interactions with medications, including anticoagulants or corticosteroids commonly used in lymphoma management.

Oncologists consistently advise patients to disclose all supplements—including pine pollen—to their care team before initiating or continuing use. Decisions about complementary therapies should be guided by evidence-based medicine and individualized risk–benefit assessment, not anecdotal reports or traditional claims. Nutrition support during NHL treatment is best achieved through balanced, medically supervised dietary strategies that prioritize food safety, adequate protein intake, and avoidance of unproven interventions that may compromise treatment efficacy or safety.